

December
1st & 2nd - 2015
Strasbourg - France

4TH
Edition



Biofit

**FOSTERING
INNOVATION
& TRANSFER**



A 360° approach to build
Life Sciences partnerships



PROGRAM



Organized by
 **eurasanté**
Invest for Success




**Alsace
BioValley**


 **conectus**
SATT ALSACE

Thank you

Gold sponsors



Silver sponsors



Bronze sponsors



Contributing sponsors



Institutional partners



Summary

About the Organizers	4
Steering Committee.....	5
Agenda	6
Day one	6
Day two.....	8
BioFIT: an international partnering event.....	11
Program	13
PLENARY SESSION: Who drives innovation in life sciences: academia or industry?.....	13
Best practices in collaborative research	14
Key issues in licensing and tech transfer	18
Early stage innovation: identify the right funding sources	22
TechnoMarket & Presenting Technologies.....	24
Hosted Events	28
Floor Plan	31
Exhibitors.....	32
Partners & Sponsors.....	42
Find your way through BioFIT	43



OUR MISSION: THERAPEUTIC AND DIAGNOSTIC INNOVATION

GENFIT is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in fields of high medical need due to a lack of suitable treatment and an increasing number of patients worldwide.

GENFIT's R&D efforts are focused on bringing new medicines to market for **patients with metabolic, inflammatory, autoimmune and fibrotic diseases**, that affect the liver (such as NASH - Nonalcoholic steatohepatitis) or **the bowel**.

Elafibranor is GENFIT's lead pipeline product for the treatment of **NASH**, a major recognized unmet medical need.

Connect together

 Genfit
 @genfit_pharma

+33 (0)3 2016 4000

www.genfit.fr

About the organizers



Eurasanté is the economic development

agency focusing on biotech, nutrition and healthcare activities in Northern France. It assists French and foreign companies interested in developing their activities or setting-up a business in Northern France. Eurasanté provides many services such as aid in accessing public subsidies, support in real-estate research, assistance with administrative formalities, human resources services, market and regulatory expertise... It also promotes the Eurasanté Bio-business Park, which already hosts 7 hospitals, 4 universities, 7 specialized schools and more than 150 companies. It benefits from an exceptional location in the heart of Europe (near Paris, London, Brussels...).

www.eurasante.com



NHL Cluster is a dynamic network focusing on today's main health issues, at the crossroads of Nutrition,

Biotechnology, and Health. Its mission is to federate and support players in the Food and Health sectors in designing, developing, and financing the products and processes of the future. In the Health sector, NHL focuses on developing preventive, diagnostic, and therapeutic solutions applicable to cardiovascular and metabolic conditions, neurodegenerative diseases and Inflammatory Bowel Diseases (IBD). Its projects in the Food sector aim at protecting health and well-being through a safe, healthy, and sustainable diet.

www.nhl-cluster.com



As a French world-class cluster dedicated to therapeutic innovations, Alsace BioValley is the one-stop contact to optimize any R&D development or

business project in Europe, both in drug development and medical technologies. Located in Alsace region, part of the famous French-German-Swiss BioValley and with a unique concentration of international life sciences & healthcare players, Alsace BioValley helps any Life Sciences & Healthcare companies interested in new projects and partnerships in Europe: to search outstanding scientific or industrial partners to develop very innovative R&D projects, to find the best innovative technology, patent or scientific expertise, or to set up and locate in Alsace region. Alsace BioValley has also agreements with CQDM (Quebec), MLSC (Massachusetts – USA), JBA (Japan Bioindustry Association) and Biopro (Germany).

www.alsace-biovalley.com



Conectus Alsace was the first SATT (Accelerator of Technology Transfer) that

has emerged in France within the Call for Projects of the Program "Investments for the future". 100% funded by the State through the National Valorization Fund operated by the French National Research Agency, Conectus Alsace operates under the private law statute, whose shareholders include: the University of Strasbourg, the CNRS, the University of Haute-Alsace, Inserm, INSA of Strasbourg, the ENGEEES and the Caisse des Dépôts et Consignations that brings the participation of the State.

www.conectus.fr

.... Steering Committee

Pharma, Biotech



Zeina ANTOUN
Clinical Research Director,
GlaxoSmithKline



Maria BOBADILLA
Senior Director, Extending
Innovation Network, Roche



Adrian CARTER
Corporate Vice President,
Global Research Networking,
Boehringer Ingelheim



Mohammed CHARKI
Research & Development
Partnerships Director, Global
Project Leader Online Open
Innovation, Sanofi



Sami CHTOUROU
Director of technology platforms
and innovation, LFB



Isabelle DIEUZY-LABAYE
Director, Strategic Alliances,
Zoetis



Maria M. FLOCCO
Senior Director, Head Strategic
Research Partnerships Europe,
Pfizer



Guy HELIN
CEO, Syngulon



Tomas LANDH
Vice President, Innovation
Sourcing, Novo Nordisk



Stephan LENSKY
Chief Operating and Chief
Business Officer, EpimAb
Biotherapeutics



Frédéric SCAEROU
Director, Scientific Affairs
Oncology, Ipsen Innovation



Pascal RAOUL
Scientific and Innovation Director,
Ceva Animal Health

Associations, Clusters, Investors & Law firms



Richard BERGSTROM
General Director, EFPIA -
European Federation of
Pharmaceutical Industries and
Associations



Claude-Alain CUDENNEC
General Director, AFSSI - French
Association of Outsourcing and
Innovative Companies



Isabelle DIAZ
Research & Biotechnology
Director, LEEM / General
Secretary, ARIIS - Alliance pour
la Recherche et l'Innovation des
Industries de Santé



Marco FIORINI
General Secretary, Aviesan -
French National Alliance for Life
Sciences and Health



Didier FROMMWEILER
General Director, Alsace
BioValley



Emilie ROYERE
Director, Eurobiomed



Cécile THEARD-JALLU
Partner Attorney, De Gaulle
Fleurance & Associés



Etienne VERVAECKE
General Manager,
Eurasanté & NHL Cluster

Academia, TTOs



Hervé ANSANAY
Business Developer, SATT Nord



Ivan BAINES
Chief Operating Officer, Max
Planck Institute of Molecular Cell
Biology and Genetics



Garold BREIT
Principal, Breit Ideas



Jean-Luc CHAGNAUD
Healthcare Business
Development Manager &
Intellectual Property Manager,
Aquitaine Science Transfert



Esther LANGE
Industry Liaison Manager,
Ascenion



Nicolas CARBONI
President, SATT Conectus Alsace

"I think it is a very exciting time for BioFIT and biomedical innovation today. What we are seeing is that the internet and the principles of open innovation have opened up a plethora of new opportunities. Over the last several years we have seen our industry extending its partnership models beyond classical bilateral agreements between academia and industry. Indeed, we are registering a move towards precompetitive public-private partnerships. We're also looking to crowdsourcing as a way of finding new ideas. We are continually searching for that secret ingredient that we can take and turn into a medicine that delivers real value to patient's lives."



Adrian Carter
Corporate Vice-
President, Global
Research Networking,
Boehringer Ingelheim




















Day one

Tuesday - December 1st


	CONFERENCES					
	 TRACK 1: Best practices in collaborative research	 TRACK 2: Key issues in licensing and tech transfer	 TRACK 3: Early stage innovation: identify the right funding sources	TechnoMarket & Presenting Technologies session	Partnering	
8:30 am 9:00 am	Registration and Exhibition opening/ Welcome coffee				Registration and Exhibition opening/ Welcome coffee	
9:00 am 10:30 am	Getting close to the action: new collaborative models to source innovation  PASTEUR ROOM (Exhibition Hall)				 One-to-one meetings	
10:30 am 10:45 am	 Coffee break				 Coffee break	
10:45 am 12:30 pm	PLENARY SESSION: Who drives innovation in life sciences: academia or industry?  SCHUMANN ROOM				PLENARY SESSION: Who drives innovation in life sciences: academia or industry?  SCHUMANN ROOM	
12:30 pm 2:00 pm	 Lunch				 Lunch	
2:00 pm 3:30 pm	How can Open Innovation be a powerful driver for the OneHealth dynamics?  SCHUMANN ROOM (1st floor)	Shaping the future of Open Innovation: does IP legal framework need a remodelling?   BOSTON ROOM (1st floor)		North America vs Europe vs Asia : how do VCs assess risk?  PASTEUR ROOM (Exhibition Hall)	Presenting technologies Cardio metabolic diseases  OBERLIN ROOM (1st floor)	
3:30 pm 4:00 pm	 Coffee break				 Coffee break	
4:00 pm 5:30 pm		Networks and alliances with the industry: how can TTOs contribute to their success?  SCHUMANN ROOM (1st floor)		The funding challenge: find alternative approaches to financing innovation  PASTEUR ROOM (Exhibition Hall)	Presenting technologies Devices & Imaging  OBERLIN ROOM (1st floor)	
7:00 pm	 Networking evening BioPARTY				 Networking evening BioPARTY	

Day two


Wednesday, December 2nd

CONFERENCES					
 TRACK 1: Best practices in collaborative research		 TRACK 2: Key issues in licensing and tech transfer		 TRACK 3: Early stage innovation: identify the right funding sources	
				TechnoMarket & Presenting Technologies session	Partnering
8:30 am 9:00 am	Registration and Exhibition opening/ Welcome coffee			Registration and Exhibition opening/ Welcome coffee	
9:00 am 10:30 am		University spin-offs: how to optimize the business and university interests/ is it easy to balance?  PASTEUR ROOM (Exhibition Hall)		How to partner more efficiently with patient groups, charities & foundations?  SCHUMANN ROOM (1st floor)	Presenting technologies Infectious diseases & Vaccines  OBERLIN ROOM (1st floor)
10:30 am 11:00 am	 Coffee break			 Coffee break	
11:00 am 12:30 pm		How to approach capacity building technology transfer?   PASTEUR ROOM (Exhibition Hall)		Does crowd funding have a place in drug development?  SCHUMANN ROOM (1st floor)	Presenting technologies Immunology & Oncology  OBERLIN ROOM (1st floor)
12:30 pm 2:00 pm	 Lunch			 Lunch	
2:00 pm 3:30 pm	Precompetitive collaborations: sharing knowledge, but is there a tangible outcome?  SCHUMANN ROOM (1st floor)	How to implement and perform effective scientific and technological due diligence?  PASTEUR ROOM (Exhibition Hall)			
3:30 pm 4:00 pm	 Coffee break			 Coffee break	
4:00 pm 5:30 pm	Four hands on the steering wheel? How are academia/industry alliances managed?  SCHUMANN ROOM (1st floor)				

Conference on biobanking:
Accelerate biomarker development and translational research optimization
By INSERM
BOSTON ROOM (1st floor)



BIOMEDICAL RESEARCH, INNOVATION



One-to-one meetings

Conference on biobanking:
Accelerate biomarker development and translational research optimization
By INSERM
BOSTON ROOM (1st floor)



One-to-one meetings

BUILD VALUE THROUGH PARTNERING

STEP ONE:

Meet at BioFIT 2015 through **partneringONE**®

The leading conference solution for helping you:

- profile your products, technologies and expertise
- use advanced search functions to find potential partners
- meet efficiently and effectively

STEP TWO:

Follow up your event meetings on **partnering360**®

The online network of life science dealmakers providing essential tools to help:

- manage post-event followup
- find new partners between events
- improve partnering productivity year round

For more information please contact the Partnering Desk or visit ebdgroup.com/partnering.services.

EBDGROUP

BioFIT

Where collaborative research & tech transfer alliances get started

Featuring partneringONE system, the business convention enables you to meet up to 30 companies over 2 days, an opportunity to boost up licensing deals and perform strategic partnerships!

powered by

partneringONE®
a product of **EBD**GROUP

About the participants

■ 35 %

Technology transfer professionals, IP and licensing / Research institutes / Academia

Ascenion, Aviesan, INPI, Inserm Transfert, Karolinska Institute, King's College London, Max Planck Institute of Molecular Cell Biology and Genetics, Oxford University, Pasteur Institute, SATT Network...

■ 35 %

Biotech, R&D services companies

Adocia, ADX NeuroSciences, Aptuit, Atlanbio, Eurofins, Galapagos, Genfit, LFB, Magmatics, Menarini, Syngulon...

■ 20 %

Pharma, Medtech, IVD companies

AstraZeneca, ABD Serotec Bio-Rad Company, Boehringer Ingelheim, GSK, Ipsen Innovation, J&J Innovation, Lilly, Merck, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Zoetis...

■ 10 %

Investors, Consulting & Professional Services

Absiskey, Alma Consulting, De Gaulle Fleurance & Associés, Erdyn, Index Ventures, Lonza, Quintiles...

More than 1,000 key players from 31 countries around the world



Catalent

NEW OPTIFORM®
SOLUTION SUITE

enhanced
bioavailability
in 12 weeks!

EASIER

Integrated solution at one simple price
with minimal material needed.

SIMPLER

Optimal recommendations based on real
data from a dedicated scientific advisor.

FASTER

Accelerated parallel process with superior
technologies allowing for optimized
animal pK materials in 12 weeks!

**Rigorous science. Superior technologies.
From molecule to dose form.**

Learn more at catalent.com/optiform

US +1 888 SOLUTION

EU +800 8855 6178

solutions@catalent.com



DEVELOPMENT

DELIVERY

SUPPLY

© 2015 Catalent Pharma Solutions.
All rights reserved.

Plenary session

Schumann Room - December 1st - 10:45 am - 12:30 pm

" Who drives innovation in life sciences: academia or industry? "

Academia often feels that industry doesn't truly understand the opportunities represented by academic research, mechanisms that haven't been exploited yet for drug development. Industry likewise claims that academia doesn't understand the constraints in terms of the reality of bringing a benefit of research to the market or for it to be made available for use by society.

So, who drives innovation in the life sciences: academia or industry?

Join our speakers to explore this hot topic!



Better Health, Brighter Future

We're driven to improve people's lives.

Takeda strives toward better health for people worldwide through leading innovation in medicine. At Takeda, we make a commitment to make a difference.



Moderator

John Carroll

Editor-in-chief, FierceBiotech

Speakers

Ivan Baines

Chief Operational Officer, Max Planck Institute of Cell Molecular Biology and Genetics

Alexander Von Gabain

Deputy Vice-Chancellor for Innovation and Commercial Outreach, Karolinska Institute

Jochen Maas

General Manager, R&D, Sanofi-Germany

Kurt Hertogs

Head Platform Innovation & Incubator Strategy, Johnson & Johnson Innovation Centre

Marisol Quintero

CEO, BIONcoTech Therapeutics

Jean-François Mouney

CEO and Chairman, Genfit



Track 1

" Best practices in collaborative research "



December 1st: 9 am - 10:30 am - 📍 Pasteur Room

Getting close to the action: new collaborative models to source innovation

Come and join our high level panelists and discuss with them:

- which new collaborative models have been put in place
- how are they organized (management of IP, conflicts of interest, publication policies, funding, leadership)
- what are the strengths and challenges facing these models?

Chairman

🇪🇸 [Alvaro Arjona](#)

Editorial Director - Life Sciences, Thomson Reuters

Speakers

🇫🇷 [Odile Piot-Grosjean](#)

Strasbourg R&D Site Director, Sanofi

🇨🇦 [Max Fehlmann](#)

President and CEO, Neomed Institute

🇳🇱 [Jon De Vlieger](#)

Call Director European Lead Factory, TI PHARMA

🇩🇪 [Ulf Nehrbass](#)

Director, Ksilink

🇬🇧 [Hitesh Sanganeer](#)

Director of Emerging Innovations - Scientific Partnering & Alliances, AstraZeneca



December 1st: 2 pm – 3:30 pm - 📍 Schumann Room

How can Open Innovation be a powerful driver for the OneHealth dynamics?

Let's discuss with our panel of experts:

- which type of collaborations can be put in place? are there successful examples? (ex: sharing of compound libraries between animal and human health researchers, the development of new in vivo models at the preclinical research stage in order to accelerate the development of new medicines, etc)
- what are the limits to such collaborations?
- what can we do to boost concomitantly OI and One Health?

Chairman

🇫🇷 [Thierry Pineau](#)

Director, Meta-program Animal Health, INRA

Speakers

🇳🇱 [Sven Arnouts](#)

Business Development Manager, Provaxs

🇫🇷 [Matthieu Dubruque](#)

COO, OCR - Oncovet Clinical Research

🇳🇱 [Emmanuel Hanon](#)

Senior Vice President, GSK Vaccines

🇫🇷 [Isabelle Dieuzy-Labaye](#)

Director, Strategic Alliances, Zoetis

🇺🇸 [Dan Peizer](#)

Director, Global Sales & Marketing, Animal Health, Catalent Pharma Solutions



December 2nd: 2 pm – 3:30 pm - 📍 Schumann Room

Precompetitive collaborations: sharing knowledge, but is there a tangible outcome?

Even though there is very little downside to precompetitive agreements except for the inability to own the technology, some issues arise concerning, antitrust issues, how to calculate payback and how to converge the information at each stage of the maturation in R&D processes. Let's discuss all these points with our top notch speakers.

Chairman

🇬🇧 [Gerald Law](#)

CEO, UK Innovation Forum

Speakers

🇵🇱 [Magda Chlebus](#)

Director Science Policy, EFPIA

🇬🇧 [Wen Hwa Lee](#)

Strategic Alliances Manager, University of Oxford
Nuffield Department of Medicine

🇩🇪 [Tomas Landh](#)

Vice President, Innovation Sourcing,
Novo Nordisk

🇫🇷 [Hüseyin Firat](#)

President & CEO, Firalis



December 2nd: 4 pm – 5:30 pm - 📍 Schumann Room

Four hands on the steering wheel? How are academia/industry alliances managed?

When creating a new alliance, the decision on who will control the direction of the collaboration is as important as the structure of the agreement itself. Will it be a joint steering committee with equal representation, will it be individuals who understand both parties (academics and industry)? And what are the concerns expressed by both parties when choosing one or the other option? Come and join our experts and debate on this topic!

Chairman

🇳🇱 [Pascale Redig](#)

Sr Category Manager Research & Academic Partnerships, Janssen

Speakers

🇬🇧 [Jutta Roth](#)

Business Development Manager,
University of Oxford

🇳🇱 [Jurgen Joossens](#)

Coordinator ADDN, University of Antwerp

🇨🇭 [Maria Bobadilla](#)

Senior Director, Extending Innovation Network,
Roche

🇳🇱 [Jan Van der Schueren](#)

Discovery Site Head, Galapagos



GSK, A key player in R&D

GlaxoSmithKline is a science-led global healthcare company that researches and develops a broad range of innovative medicines and brands. Our products are used by millions of people around the world, helping them to do more, feel better and live longer.



We have three primary areas of business in pharmaceuticals, vaccines and consumer healthcare. Our commercial success depends on creating innovative new products and making these accessible to as many people as possible. By achieving this, we will be able to grow our business and provide benefits to patients, consumers, society, our employees and our shareholders.

Our headquarters are based in the UK, and we have a wide geographical

reach. We have offices in more than 115 countries, major research centres in the UK, USA, Spain, Belgium and China and an extensive manufacturing network with 87 sites globally.

Research is vitally important to the success of our business, and we spent just under £4 billion each year in our search to develop new medicines, vaccines and innovating consumer products. We are one of the few healthcare companies researching medicines and vaccines for the World Health Organisation's three priority diseases - HIV/AIDS, tuberculosis and malaria.

As a science-led global healthcare company we have the opportunity to improve the health and well-being of millions of people around the world.


Through investment in R&D and infrastructure, and through collaboration with other organisms and academic institutions, we are innovating to address currently unmet health needs. We are improving access to our products, irrespective of where people live or their ability to pay, and we are working to control or eliminate diseases affecting the world's most vulnerable people.

*Lilly unites caring with discovery
to make life better for people around the world*

Lilly associe soins et découvertes pour améliorer la vie de chacun dans le monde

Lilly France 24 boulevard Vital Bouhot
CS 50004 - 92521 Neuilly sur Seine Cedex
Tél. : 01 55 49 34 34 - Fax : 01 41 44 02 47
www.lilly.fr - S.A.S. au capital de 358 511 701 €
609 849 153 R.C.S. Nanterre

Lilly





Track 2

"Key issues in licensing and tech transfer"



December 1st: 2 pm – 4 pm - ♀ Boston Room



Shaping the future of Open Innovation: does the IP legal framework need a remodeling?

Open innovation and good IP management are not mutually exclusive, one can naturally enhance the other, far from working against each other, they work together. IP management is what makes Open-Innovation possible and hence, Open-Innovation and IP management have to go hand in hand to grab the million opportunities to be captured. IP can be viewed as a way to protect innovations as well as a way to block technologies, but the key question is : should we really modify IP law or should we simply modify the way it is used?

Chairman

[Timo Minssen](#)

Associate Professor, University of Copenhagen

Speakers

[Philippe Borne](#)

Regional Representative in Strasbourg, INPI

[Katya Ascher](#)

IP Attorney, Mishcon de Reya

[Gauthier Obrecht](#)

Patents Biotech, Boehringer Ingelheim

[Sumitra Rajagopalan](#)

CEO, Bioastra Technologies



December 1st: 4 pm – 5 :30 pm – ♀ Schumann Room

Networks and alliances with the industry: how can TTOs contribute to their success?

Industry is increasing its partnering activities with research institutions by creating new alliances and platforms for open innovation. TTOs have an important role to play in putting in place these collaborations and that is beyond dealing with IP issues

This session will discuss:

- How can TTOs contribute to the success of these partnerships?
- What works and what doesn't
- Which challenges are TTOs facing?
- What are the industry's expectations?"

Chairman

[Guy Helin](#)

CEO, Syngulon

Speakers

[Holger Schwarz](#)

Director - Head of Innovation Opportunities Europe, Merck Serono

[Matthias Stein-Gerlach](#)

Patent and Licensing Manager, Max Planck Innovation

[Luigi Aurisicchio](#)

CEO, Takis

[Mike Johnson](#)

Director of Corporate Partnerships, MRC Technology



December 2nd: 9 am – 10:30 am - ♀ Pasteur Room

University spin-offs: how to optimize the business and university interests/ is it easy to balance

When creating a spin-off from the university, there is a need for a balance in decision making between the company and university, and the separation of responsibilities of corporate and university employees. Join us and share your expertise on how to correctly put in place a checks –and– balances system that will help keep the interrelations synergetic and drive the company forward?

Chairman

[Christophe Lecante](#)

CEO, TKM

Speakers

[Koen Dewaele](#)

CEO, ADX Neurosciences

[Christian Stein](#)

CEO, Ascenion, President, ASTP-Proton

[Simao Soares](#)

CEO, SilicoLife

[Jaromir Zahradka](#)

Business Development Manager, IOCB TTO



December 2nd: 11 am – 12:30 pm - ♀ Pasteur Room

How to approach Capacity Building technology transfer?

Is there a "one size fits all" solution? Is The Best Practice transferable to every TTO in every country and applicable in each (regional) situation? ASTP-Proton invites you to this interactive session to share your expertise and explore the possibilities to come to a better common understanding of CBTT.

Speakers

[Erik Vane](#)

General Director, ASTP-Proton

[Christian Stein](#)

President, ASTP-Proton, CEO, Ascenion

[Jon Wulff Petersen](#)

Member of the Board, ASTP-Proton, CEO, TTO A/S



December 2nd: 2 pm – 3:30 pm - ♀ Pasteur Room

How to implement and perform effective scientific and technological due diligence?

Scientific and technological due diligence requires a relatively high priority and measures need to be taken from the very beginning of the company in order to be prepared for it. Our panelists will tackle issues on how to best prepare for this process, how long the process last, what the expectations are on pharma's side and give some advice from their own experience.

Chairman

[Diane Seimetz](#)

Co-Founder, Biopharma Excellence

Speakers

[Carl Jessop](#)

Due Diligence Director, AstraZeneca

[David Malek](#)

VP Business Development, BioLineRX

[Martin Cadman](#)

Director, Scientific Licensing, GSK

[Cécile Théard-Jallu](#)

Partner, De Gaulle Fleurance & Associés



Working together for better health

At Boehringer Ingelheim we believe in forming durable partnerships to develop innovative new medicines in areas of high unmet need. Our relationships range from discovery research, development and technology collaborations to clinical and commercial partnerships and full-scale, long-term strategic alliances.

Boehringer Ingelheim is researching, developing, manufacturing and marketing new medications of high therapeutic value for patients. It is one of the world's 20 leading pharmaceutical companies and operates globally with a total of more than 47,700 employees. In 2014 Boehringer Ingelheim achieved net sales of about 13.3 billion euros and spent 2.7 billion euros on R&D corresponding to 19.9 per cent of its net sales.

We invite you to find out more about partnering with us by visiting <http://partnering.boehringer-ingelheim.com>



Sanofi Pasteur

www.sanofipasteur.com

SANOFI PASTEUR

Partnership opportunities with Sanofi Pasteur

Sanofi Pasteur, the vaccines division of Sanofi, is seeking partners who will share the company's pursuit of innovation and drive for excellence. Our diverse culture and geography allow us to collaborate effectively with a broad array of partners around the world.

We are not only at the forefront of conquering newly targeted infectious diseases, but also leading the way in expanding immunization across all age groups, including adolescents and the elderly. This leadership has translated into outstanding success in the industry, and our company has experienced a recent period of unprecedented growth.

Sanofi Pasteur is interested in partners who will share in the pursuit of innovation and our drive for excellence, while becoming a part of our market success story. "We welcome the opportunity to evaluate technologies related

Sanofi Pasteur is interested in potential partnering opportunities in the field of active and passive human immunization, as well as technologies supporting product development and industrial performance, including:

Vaccines, monoclonal antibodies and supporting technologies for prevention and treatment of infectious diseases

- Novel antigens and methods for antigen discovery and characterization
- Vaccine vectors suitable for nasal or oral use
- New ways to administer vaccines
- Carrier proteins and protein-polysaccharide conjugation methods or alternative technologies

Agents to enhance vaccine immune responses

- Adjuvants and immunomodulators
- Vaccine vectors and delivery systems intended to enhance or modify immune responses
- Biological and immunological studies to further characterize adjuvants and immunomodulators

Characterization and assay of immune responses and disease markers

- Animal models of human diseases
- Biological markers for evaluating the efficacy of prophylactic or therapeutic interventions
- *In vitro* models of human tissues, including the immune system
- Epidemiological studies relevant to the use of vaccines and immunotherapeutics

Tools for improving vaccine and monoclonal antibody research, development and production

- Development and application of new technologies in the areas of genomics and proteomics
- Prokaryotic or eukaryotic cell lines for antigen production
- Fermentor and bioreactor technology
- Disposable systems
- Online testing
- Downstream processing, purification and aseptic filling processes
- Process automation
- Preservatives and stabilizers
- Bioinformatics techniques for modeling, data handling and analysis
- Anti-counterfeiting technology



Sanofi Pasteur recently signed an agreement with SK Chemical Co. of South Korea to co-develop an innovative pneumococcal conjugate vaccine

to the development and production of human vaccines, both prophylactic and therapeutic, including vaccines for infectious and chronic diseases," said Roman Chiciz, PhD.

Sanofi Pasteur has a strong commitment to Research and Development partnerships with major universities, research institutes, government bodies, biotechnology companies and contract research organizations. The company's collaborations cover virtually all aspects of vaccine development, including early-stage research.

Examples of current partnerships and technology investments include: vaccines for dengue fever, Japanese encephalitis, *S. pneumoniae*, and *M. tuberculosis*; pediatric combination vaccines; rabies monoclonal antibodies; large-scale, cell culture-based virus production; adjuvants and immunomodulators; conjugate vaccine production; and vaccine delivery systems.

A company partnering with Sanofi Pasteur interacts with a multidisciplinary team that has years of experience in working to ensure that partnerships are executed successfully and nurtured for the mutual benefit of all parties.

This approach utilizes the value-added Sanofi

Pasteur alliance management capability, which focuses on the relationship by facilitating open communication, trust, understanding and clear expectations across the project lifespan. Combined with the technical competency of the alliance, this balance provides a well rounded environment for your technology to flourish.

CONTACT DETAILS

Sanofi Pasteur welcomes information about new partnership opportunities. Each opportunity is carefully evaluated and reviewed by our dedicated team.

Please contact:

Roman Chiciz, PhD
Head, External Research and Development
Tel: +1 617 866 4562
Email: roman.chicz@sanofipasteur.com

Jean-Marc Renard, MS, MBA
Vice President, Corporate Development
Tel: +33 4 3737 3480
Email: jean-marc.renard@sanofipasteur.com

BIGNON LEBRAY
AVOCATS

www.bignonlebray.com

Corporate | Tax | Intellectual Property

For 15 years, BIGNON LEBRAY has been advising Start-ups, Young Innovative Companies, Gazelles and Unicorns on all their innovative projects.

Contacts :
Thomas BUFFIN (Lille)
tbuffin@bignonlebray.com
Edouard WAELS (Paris)
ewaels@bignonlebray.com



Track 3

"Early stage innovation: identify the right funding sources"



December 1st: 2 pm – 3:30 pm - 📍 Pasteur Room

North America vs Asia vs Europe: how do VCs assess risk?

As the saying goes, every land has its own law. This also applies to VCs and investors over the world. Let's tackle with our panel of experts whether investors perceive risks in the same way in different regions of the globe. On which criteria they invest and what are their expectations?

Chairman

 [Gary Breit](#)

Principal, Breit Ideas

Speakers

 [YenChen Huang](#)

Senior Assistant Vice President, Diamond BioFund
CEO, Biophytis

 [Stanislas Veillet](#)

Senior Associate, Sofinnova Partners

 [Sara Nunez Garcia](#)

Senior Director, Investments, Life Sciences,
Fonds de solidarité FTQ

 [Didier Leconte](#)



December 1st: 4 pm – 5:30 pm - 📍 Pasteur Room

The funding challenge: find alternative approaches to financing early stage innovation

In recent years, unconventional sources to fund innovation have appeared and the financing models are evolving. This panel will discuss these trends as they aim to answer the question on everyone's mind—who is financing early stage innovation and what are their expectations in terms of business models & level of maturity?

Chairman

 [Nicolas Carboni](#)

President, SATT Conectus Alsace

Speakers

 [Kevin McBride](#)

Director, Project Management, AmorChem

 [Andrew Parker](#)

General Partner, Ecllosion

 [Serge Braun](#)

Scientific Director, AFM

 [Dieter Ziegler](#)

Director - Search and Evaluation Europe, AbbVie



December 2nd: 9 am – 10:30 am - 📍 Schumann Room

How to partner more efficiently with patient groups, charities & foundations?

Charities and foundations have been increasingly supporting start-up companies and even early-stage projects thus helping to fill the financing gap in life sciences. How can these funding sources be accessed? What are their expectations? How to attract this group to finance early stage projects and thus create value and impact for our institutions and society?

Chairman


 [Thomas Dentzer](#)

General Manager,
Luxembourg BioHealth Cluster

Speakers

 [Sohini Chowdhury](#)

Senior VP of Research Partnerships,
The Michael J. Fox Foundation

 [Jérôme Van Biervliet](#)

Senior Business Development Manager, VIB

 [Olivier Arnaud](#)

Director Research Europe, JDRF

 [Robin Rasor](#)

Managing Director of Licensing,
University of Michigan




December 2nd: 11 am – 12:30 pm - 📍 Schumann Room

Does crowd funding have a place in drug development?

Crowdfunding platforms with a specialist focus on life sciences have now started to emerge, and some are introducing new investment models. Does this represent a passing fad? Or the beginning of something big? How will stock exchanges (the ultimate crowdfunding platforms) engage with crowdfunding platforms? Which biotech companies should engage with them? And how? Join our panelists to explore the potential for crowdfunding in drug development.

Chairman

 [Cormac Sheridan](#)

Journalist, BioWorld Today

Speakers

 [Daniel Oliver](#)

CEO, Capital Cell

 [Ajan Reginald](#)

Executive Director, Cell Therapy

 [Fabrice Beauchene](#)

CEO, My Pharma Company

 [Mohammed Charki](#)

Research & Development Partnerships Director,
Sanofi

TechnoMarket & Presenting Technologies

Ready to be licensed!

Let's discover Life Sciences latest innovations

Discover nearly 100 projects at the Poster Area and listen to the pitches of the 36 most innovative projects selected by our jury of experts, in the following categories:

- Cardio metabolic diseases
- Devices & Imaging
- Infectious diseases & Vaccines
- Immunology & Oncology

Want to know more about the selected projects?

Get the "Oral Presentations Book" displayed at the Poster Area (1st floor) or ask our team.


Co-organized with:



Supported by:



📍 Oberlin room (1st floor)



Agenda

Day 1 - Dec. 1st - 📍 Oberlin room (1st floor)

Cardio metabolic diseases

2 :00pm – 3 :30pm

Moderator:

To be defined -

Pitches:

1. APTEEUS : Engaging Patients in Drug Discovery - APTEEUS
2. Cardiogel - SATT Ouest Valorisation
3. Circulating CD36 : A predictive marker for diabetes and atherosclerosis - Aalborg University Hospital
4. Coronary Artery Diseases Diag - SATT Sud Est
5. Heart Attack - SATT Sud Est
6. LIGAN-PM - UMR 8199 LIGAN
7. Nanotechnology-based development of novel «artificial islets» inducer in vitro – Bar Ilan University & Institute of Nanotechnology & Advanced Materials

Devices and Imaging

4 :00pm – 5 :30pm

Moderator:

Peggy Baudouin-Cornu - Medical Devices Project Manager, Aviesan (FR)

Pitches:

1. APIOS - Linkium SATT GIFT
2. Brachytherapy : Autonomous Robot for prostate brachytherapy - SATT Nord
3. Diabetachip : A new device for real-time analysis of pancreatic beta-cells and islets - SATT Aquitaine Science Transfert
4. FIBIR Detection and classification of liver fibrosis from serum by infrared spectroscopy - SATT Nord
5. Image-guided deep brain stimulation - SATT Ouest Valorisation
6. Reg Tex - SATT Sud Est
7. RNA/DNA Drug delivery NP systems - Bar-Ilan University & Institute of Nanotechnology & Advanced Materials
8. TACN : 1,4,7 triazacyclonmane - Welience SATT Grand Est

Day 2 - Dec. 2nd - 📍 Oberlin room (1st floor)

Infectious diseases and Vaccines

9 :00am – 10:30am

Moderator:

Ulrich Kinzel - Managing Director, Goetzpartners (DE)

Pitches:

1. ACROSS - SATT Nord
2. BacVac - APCure
3. CARROUCELL - Linkium SATT GIFT
4. FluGP : Optimization of Influenza vaccine antigens production using reverse genetics - Pulsalys SATT Lyon St Etienne
5. In vitro and in vivo platform for addressing antibiotic resistance - Vaxinfectio
6. PEPSTAF : Antibacterial peptides for multi-drug resistant bacteria - SATT Ouest Valorisation
7. Platform for conducting vaccine trials - Vaxinfectio
8. Smart microneedles patches for dermal delivery - MyLife Technologies BV

Immunology and Oncology

11:00am – 1:00pm

Moderator:

Jean-Claude Muller - Special Advisor Innovation & International Relationship (I&IR), BioB Innovation (FR)

Pitches:

1. Beta peptide macrocycles for therapy : On-demand beta peptide libraries – Chromacon
2. Bio-specific and Bio-stable Reagent for Thiols Ligation - SATT Conectus
3. CINSARC : Complexity INdex in SARComas - SATT Aquitaine Science Transfert
4. Diagnostic kit for acute GvHD prediction - SATT IDF Innov
5. ERK inhibitors for the treatment of RAF and RAS mutated cancers - AVG Discovery
6. Hepatomir : miRNAs-replacement therapy for treating hepatoblastoma - SATT Aquitaine Science Transfert
7. IMIQUALINES - SATT AxLR
8. LTVax : A therapeutic vaccine for lung cancer treatment based on BacVac - APCure
9. Microparticulosome Signature - SATT Sud Est
10. PEPTIDOTS : A unique non-denaturing process for protein encapsulation - Carlina Technologies
11. Predictive Biomarkers for early identification of patients at risk of acute lung injuries - Aalborg University Hospital
12. PREDMED : Molecular diagnostic tool - SATT Conectus



A BIOPHARMACEUTICAL GROUP COMMITTED TO THE LIFE

OF HUNDREDS OF THOUSANDS OF PATIENTS SUFFERING FROM SERIOUS AND OFTEN RARE DISEASES WHO ARE TREATED EACH YEAR WITH OUR BIOPHARMACEUTICALS.

The LFB Group specializes in biopharmaceuticals: plasma-derived medicinal products, recombinant proteins, monoclonal antibodies and advanced therapies.

The LFB Group manufactures its biological medicines in 5 bioproduction plants – 4 of which are in France – and markets its products in more than 40 countries.

www.lfb.fr

Follow us on social networks



CONNECTED TO LIFE SCIENCES

WE COVER ALL LEGAL NEEDS OF LIFE SCIENCES ACTORS
FOR TRANSACTIONAL, REGULATORY AND LITIGATION MATTERS



Your contacts at the Biofit 2015 conference:

Cécile Théard-Jallu,
Partner

+ 33 (0) 6 61 92 05 29
ctheardjallu@dgfla.com



Francine Le Péchon-Joubert,
Partner

+33 (0) 6 98 51 94 24
flepechonjoubert@dgfla.com



DE GAULLE
FLEURANCE
& ASSOCIÉS

SOCIÉTÉ D'AVOCATS

100+ LAWYERS AND PARALEGALS
AN INTEGRATED
FULL SERVICE APPROACH

9, rue Boissy d'Anglas
75008 Paris - France
Tel.: + 33 (0)1 56 64 00 00

222, avenue Louise
1050 Brussels - Belgium
Tel.: + 32 (0)2 644 01 64

www.degaullefleurance.com




Partnering for the development of innovative immunotherapeutic vectors




Aiming at building a strong collaborative network for the discovery and clinical validation of both original products or combinations and for the treatment of cancer and infectious diseases

Know-how & technologies of interest



Engineering of various viral platforms (MVA, oncolytic virus, adenovirus...)
Combination with modulators of immune response (ICIs, shRNAs, bispe-MABs, etc.)

R&D collaborations



A versatile partnership model for either academia, biotech or pharma companies willing to enter into the field of viral vector-based immunotherapeutics or to bolster their internal efforts in this area.

Expertise in clinical development



An experience of 56 phase 1/2 trials and preparation of 2 global phase III trial

Funding of collaborative research



Participant or coordinator of +10 projects supported by national or international funds (EC, ANR, BPI, NIAID, etc...).

Contact :

Jean-Marc Balloul
E-mail : balloul@transgene.fr
phone: +33 3 88 84 22 26

www.transgene.fr



Johnson & Johnson INNOVATION

because a great idea CAN COME FROM ANYWHERE

Johnson & Johnson Innovation seeks to find the best science and technology, no matter where it is, to solve the greatest unmet needs of our time.

Our goal: translate cutting edge ideas into healthcare solutions for patients.

Together we can transform patient care.

www.jnjinnovation.com [@jnjinnovation](https://twitter.com/jnjinnovation)



Hosted Events

BioFIT partners with several events running before and during BioFIT. One more opportunity to meet potential R&D partners and to share best practices in various fields!

BioValley Day

BioValley Day November 30th

Before the D-Day, the most innovative world class institute and industrial players from the Franco-German-Swiss met to discuss innovative practices and trends in minimally and image-guided surgery and discover 15 promising Life Sciences start-ups looking for funding.



Biobank: Fostering biomarker development

December 2nd - 9am to 10:30am
Boston room (1st floor)

This presentation focuses on biomarker development and translational research optimization by taking into account the role of biobanks and public-private partnership.



INPI Conference

December 1st - 2pm to 4pm
Boston room (1st floor)

Shaping the future of Open-Innovation:
does the IP legal framework need remodeling?



December 1st

2pm to 3:30pm
Schumann Room (1st floor)

How can Open Innovation be a powerful driver for the OneHealth dynamics

Initiated by The French association for animal health industry (SIMV) "R&D dating for Animal Health and innovation" aims to initiate high-level exchanges between the research departments of the veterinary medicine and diagnostics industry and public research, as well as biotechnology companies (start-ups).

Meet the association members at the SIMV Pavilion C10.



**November 30th
& December 1st**

Organized by Eurasanté and NHL Cluster, in partnership with Lund University, Ascenion, Sanofi, Genfit, Novo Nordisk and AstraZeneca, IDEA Summit is a unique European event dedicated to collaboration, translational research & technology transfer in the field of diabetes – featuring :

1 day of conferences on the following topics :

- Pre-competitive consortia & bilateral collaborations: are these classic models enough to speed up innovation?
- How to bridge the gap between research and clinic: an overview of national initiatives
- Patient empowering: how can they get more involved in future treatment solutions and funding diabetes research?
- Most successful/innovative SMEs & start-ups in 2014/2015 in diabetes: find out their success story and financing map

1 day of networking during BioFIT business convention



December 1st & 2nd
Oberlin Room (1st floor)

The SATT network, (the association of the French TTOs), & BioFIT launch the TechnoMarket & Presenting technologies session. The TechnoMarket & Presenting technologies session aims at matching the needs of academia and TTO (or companies) seeking alliances and business development opportunities on innovative projects related to human or animal health in the following categories:

- Devices & imaging
- Cardio metabolic diseases
- Infectious diseases & vaccines
- Immunology & oncology



November 30th
Oberlin Room (1st floor)

An event to design the best relationships within the new landscape of industry R&D cooperation. In the center of the topics: the growth of small and medium "technology" companies driven by the need of biopharma companies to improve research at limited cost and by the need of academic organizations to mature the output of research programs. Organized by AFSSI, French Association of Outsourcing and Innovative Companies.

Meet the members of the association at the
AFSSI pavilion – F9



ASTP-Proton Conference

December 2nd
Pasteur Room - 11am to 12:30 pm

How to approach capacity building
technology transfer?

Venue

STRASBOURG, AN ATTRACTIVE, INNOVATION-LED EUROMETROPOLIS

The heartbeat of the Rhine basin and Alsace, Strasbourg occupies a strategic position between France, Germany and Switzerland, in the centre of Europe. The city's growth dynamic is driven by an innovative economy, a world-class university which works closely with industry, and a comprehensive real estate offering.

Strasbourg is located in the centre of the world famous biovalley (in the 3-border region shared between France, Germany and Switzerland), which is host to some 40% of the worldwide leaders in the pharmaceutical industry. Pharmaceuticals is of prime importance to Alsace as it involves some 300 companies with just under 25,000 employees, making the region the 2nd largest healthcare campus in France, just after the Greater Paris region.

Strasbourg, European capital


Rich of 2,000 years of history and exchanges, Strasbourg is a symbol in the heart of Europe. The city with a long humanist tradition is the seat of many institutions of the European Union and of Greater Europe.

Strasbourg, a lifestyle shared with the world

Strasbourg's long tradition of hospitality makes it the ideal host for people and languages from all over the world. The city is actively committed to helping its foreign visitors feel as comfortable as possible. Some 4 million people visit Strasbourg every year, including 2 million at Christmas. There's a surprise every minute in the streets of Christmas – entertainment, friendship, music and laughter.

Strasbourg has all the assets to take on an innovative and responsible economic development dynamic resolutely turned towards Europe. In a context marked by major economic changes, our city may well assert itself as the "European laboratory" where the future is built.

Floor Plan



3M Purification E6
Absiskey B1
AdipoPhyt F6

AFSSI F9
Banook Cardibase F9
Biosims Technologies F9
Drugabilis F9
Libragen F9
Oroxcell Sas F9
Rd - Biotech F9
THERADIS PHARMA F9

ANRT/CIFRE C3
ASTP Proton D1
Atlanpole Biotherapies F5-E12
Baccinex SA E3
Bachem AG F3
BioBanques B12
Biocitech A6
Biogenouest F5-E12
BioValley Life Sciences Network C9
BluMorpho B7
Catalent Pharma Solutions D3
CEA Tech E7
Chelatec C7
CiToxLAB atlantbio F4
Clever Life Science B3
Enterprise Lithuania C4
ERDYN C8
EU-japan Centre For Industrial Cooperation B11
Eurofins Biopharma Product Testing B5
Global Care Initiative E9
HNP Mikrosysteme C2
HWI ANALYTIK GmbH D2
ID2Santé F5-E12

Infors AG E1
INPI D4
Kaly-Cell F14
Knowmade B7
Lebas Industries B10

Lille Northern France Biocluster B9
Amylgen B9
ETAP-lab B9
Eurasanté B9
Nutrition Health Longevity Cluster B9
Original Process B9

Materials Institute Carnot Alsace E5-D7
Medicen Paris Region B6
Merck E10
Nord France Innovation Développement - NFID A2
OCR C1
ONCOLille A1
Polepharma F5-E12
PRECIGENICS B2
PROSTHESIS VALLEY A7
ProteoGenix F15

R&D dating for Animal Health and Innovation - SIMV C10
CEVA Santé Animale C10
ICSA Animal Health Carnot Institute C10
MERIAL C10
VIRBAC C10
Zoetis C10

Recipharm F1

Réseau SATT F8
Linksium F8
PULSALYS SATT Lyon St Etienne F8
SATT Aquitaine Science Transfert F8
SATT AxLR F8
SATT Conectus Alsace F8
SATT GRAND CENTRE F8
SATT GRAND EST F8
SATT IDF INNOV F8
SATT Lutec F8
SATT Nord F8
SATT OUEST VALORISATION F8
SATT Paris-Saclay F8
SATT SUD EST F8
TOULOUSE TECH TRANSFERT F8

Rondol D8
RWS Translations F2
Sanofi E4-D5
Soladis Clinical Studies A5
Somalogic, Inc E8
Teclis B4
TKM E13
Zymo Research Europe GmbH E2

Coffee Break Area

Partnering Booths

Press Area

Join the BioParty to continue your networking in a friendly and festive 50's atmosphere!



Times of departures from Palais de la Musique et des Congrès :

6.00pm - 6.30pm - 7.00pm
Pick-up area : Erasme Entry - Next to the Mercure Hôtel

Music & Dancing
Glamorous show

Exhibitors

3M Purification

Boulevard de l'Oise
95006 Cergy-Pontoise - FR

Website: www.3m.fr
Phone: +33 (0)6 88 06 92 98
Contact: CLEVY Sébastien
Email: sclevy@mmm.com

Overview: 3M Purification design a wide range of solutions to meet the many processing challenges in the Biotechnology Industry : - CLARIFICATION of biological and biotechnical products, for fractioning of plasma product, DNA & HCP reduction & endotoxin removal - PURIFICATION of cell culture harvests to optimize the downstream process for target proteins (such as mAb) - STERILE FILTRATION

E6



Amylgen

2196 Boulevard de la Lironde - 34980
Montferrier sur Lez - FR

Website: www.amylgen.com
Phone: +33 (0)4 67 63 99 87
Contact: VILLARD Vanessa
Email: vanessa.villard@amylgen.com

Overview: Amylgen is a pre-clinical CRO offering validated in vivo models of neurodegenerative diseases. Amylgen is dedicated to provide our partners a comprehensive platform of models of neurodegenerative diseases and techniques for the pre-clinical evaluation of products. Amylgen has the capacity for testing in a screening mode new drugs designed for the treatment of central nervous system diseases as well as dietary supplements/ingredients with a potential medical use in the field of brain health.

B9



Absiskey

26 rue Colonel Dumont - 38000 Grenoble - FR

Website: <http://en.absiskey.com>
Phone: + 33 (0)4 86 11 01 80
Contact: GIANINAZZI Nicola
Email: n.gianinazzi@absiskey.com

Overview: Since 1988, Absiskey is a consulting company leader in public funding for research and innovation and investment. Absiskey has a team of 50 multidisciplinary consultants supporting the development of SMEs, large companies, research centers and universities across Europe. Absiskey raised more than 1.8 billion euros of public funding to 290 research and innovation collaborative projects. Absiskey is coordinator and partner of European projects in the Health and biotech sector.

B1



AdipoPhYt

91 bd de l'Hospital - 75013 Paris - FR

Website: www.adipophyt.com
Phone : +33 (0)1 40 77 96 63
Contact: BERNABEU Hervé
Email: hbm@adipophyt.com

Overview: Specialist since 2010 of the biology of human adipose tissue, AdipoPhYt has developed an evaluation platform based on human adipocyte models (preadipocytes, mature adipocytes, explants). AdipoPhYt delivers functional screenings to assess the metabolic activity, weight management, anti-aging, therapeutic effects of compounds on the biology of adipose tissue through interactive visualisations for customized reports and direct access to raw data. AdipoPhYt is part of the ecosystem of the IHU ICAN.

F6



AFSSI Sciences de la Vie

Biocitech - 102 Avenue Gaston Roussel
93230 Romainville - FR

Website: www.afssi.fr
Phone: +33 (0)3 84 58 46 85
Contact: CUDENNEC Claude-Alain
Email: cacudennec@afssi.fr

Overview: AFSSI, French Association of Outsourcing and Innovative Companies in the field of Life Sciences was born in 2012 to gather companies established in France and providing R&D services to industrial or academic partners. It is a non-profit organization headquarter in Paris region. AFSSI embraces the domain of Life Sciences at large: Biotechnology, Fine Chemistry, Cosmetology, Agro-food, Bioinformatics, Diagnostics, Clinical trials, Green business.

F9



ANRT/CIFRE

41 Boulevard des Capucines - 75002 Paris - FR

Website: www.anrt.asso.fr
Phone: +33 (0)1 55 35 25 61
Contact: ANGELIER Clarisse
Email: cifrer@anrt.asso.fr

Overview: The Cifre program, on the behalf of the French Ministry of Higher Education and research, shares your expenditures for hiring a doctoral student to whom you entrust an R&d mission. The R&d mission is carried out in the framework of a partnership with an academic laboratory. The Cifre program gathers more than 4,000 doctoral students in all academic fields and business sectors. The grant to company involved in the Cifre is € 14,000/year during 3 years for a minimum gross annual salary of € 23,484

C3



ASTP-Proton

Stationsweg 28A - 2312AV Leiden - NL

Website: www.astp-proton.eu
Phone: +31 717 113 511
Contact: WIBOWO Arlyta
Email: arlyta.wibowo@astp-proton.eu

Overview: ASTP-Proton is the premier and leading Europe-wide association for professionals involved in the transfer of knowledge, science and technology between universities and industry with more than 830 members from 41 countries. In order to facilitate the exchange of best practices among K/TT professionals and strengthen the network of our members, ASTP-Proton organises several networking events as well as professional development trainings throughout the year in various European cities.

D1



Atlanpole Biotherapies

Château de la chanterrie, 95 route de Gachet
44307 Nantes - FR

Website: www.atlanpolebiotherapies.com
Phone: +33 (0) 2 40 25 27 20
Contact: GUERINEAU Lynda
Email: guerineau@atlanpole.fr

Overview: Atlanpole Biotherapies is a French clusters dedicated to health. It gathers 92 companies, 56 research units, 2 Hospital Universities and 1 veterinary school, and has 28 EUROPEAN partners in international collaborations. Our main areas of excellence are Immunobiotherapy, Radiopharmaceuticals, Regenerative Medicine and Innovative technologies for biotherapies. Atlanpole Biotherapies mission is to boost innovation mainly through public/private partnerships and international networking.

F5 - E12



Baccinex SA

Rue de la Source 3 - 2822 Courroux - CH

Website: www.baccinex.com
Phone: + 41 32 420 76 40
Contact: BROGGI Bénédict
Email: benedicte.broggi@baccinex.com

Overview: Baccinex is the preferential and highly recognized one-stop Swiss partner (CMO) for contract manufacturing of sterile lyophilized and liquid dosage forms. We routinely supply clinical medication for phase I, II and III trials to our (bio)pharmaceutical clients.

E3



Bachem AG

Hauptstrasse 144 - 4416 Bubendorf - CH

Website: www.bachem.com
Phone: + 41 (0)5 85 95 24 65
Contact: PARMENTIER Gilles
Email: gilles.parmentier@bachem.com

Overview: Bachem provides a full range of services to the pharma and biotech industries. It specializes in the development of innovative, efficient manufacturing processes and the reliable production of peptide-based active pharmaceutical ingredients. The group has a global reach with more experience and know-how than any other company in the industry. Towards its customers, Bachem shows total commitment to quality, innovation and partnership. Bachem. Pioneering Partner for Peptides

F3



Banook Cardiabase

78 Avenue du XXème Corps - 54000 Nancy - FR

Website: www.banookgroup.com
Phone: +33 (0)3 83 39 10 10
Contact: DURAND-SALMON Alexandre
Email: alexandre.durand-salmon@banookgroup.com

Overview: Banook Group is one of the few established international providers capable of providing cardiac safety, central imaging and endpoint adjudication services to pharmaceutical, medical device and biotech companies, CROs and nonprofit organizations. Its mission is to help its clients invent tomorrow's healthcare, using qualitative, reliable and innovative solutions in early to late stage clinical trials and ultimately to bring new solutions to the market for the benefit of patients worldwide.

F9



BioBanques

Hopital de la Pitié Salpêtrière
47 boulevard de l'Hopital - 75013 Paris - FR

Website: www.biobanques.eu
Phone: + 33 (0)1 42 16 25 41
Contact: DE JOUVENCEL Tiphaine
Email: tiphaïne.de-jouvencel@inserm.fr

Overview: The national infrastructure BIOBANQUES aims to accelerate biomarker development and translational research optimization. It provides a one-step-access to biological samples from 84 biobanks and covers the whole spectrum of diseases. It also offers a variety of expert's services to meet researchers expectations and requests such as: Ethics & Regulatory issues, Methodology & Statistics, Bioinformatics and Sample Quality. 60 biotech companies have already entrust BIOBANQUES

B12



BIOCITECH

102 avenue Gaston Roussel
93230 Romainville - FR

Website: www.biocitech.paris
Phone: +33 (0)2 51 86 19 59
Contact: BOUSSARD Jean-François
Email: jean-francois.boussard@biocitech.paris

Overview: The BIOCITECH CITY COMPLEX fosters growth and innovation in the field of biotechnologies. BIOCITECH is the perfect location to develop biotechnology companies and healthcare industries (bio-informatics, medical devices and equipment, imaging, diagnostics...) The complex contributes to entrepreneurial success through the 'plug&grow' formula and provides a full range of business services with the 'plug&live' formula. BIOCITECH is expert in tailoring premises to the needs of individual businesses.

A6



Biogenouest

INRA Pegase Domaine de la Prise
35590 Saint gilles - FR

Website: www.biogenouest.org
Phone: +33 (0)2 40 25 10 88
Contact: HALLOUIN Florence
Email: florence.hallouin@biogenouest.org

Overview: Biogenouest is the Western France life science core facility network. Biogenouest allows the coordination of 32 life science core facilities in genomics, proteomics, functional exploration, bioimaging, structural and metabolomics analysis and bioinformatics. A technological core facility is a set of equipment and associated expertise, on one or more sites, which operating capacity is available to public or private clients, with a view to offering access to high-level technologies for R&D.

F5 - E12



Biosims Technologies

75 route de Lyons la Forêt - 76000 Rouen - FR

Website: www.biosims-technologies.com
Phone: +33 (0)2 32 18 48 14
Contact: BELOUARD Jean-Marc
Email: jmbelouard@biosims.eu

Overview: Quantification of low abundance proteins represents a promising new field to explore. Biosims combines biochips with mass spectrometry by using a digital quantification with an unsurpassed sensitivity proteins quantification down to the fg/ml range. Our microarrays feature multiplex spots of sandwich immunoassays, where detection antibodies are quantified using one mass-tag, thus needing no fluorescence and no signal amplification. Quantification up to 25 plex in 10 µL of sample with 5 Log Dyn.

F9



BioValley Life Sciences Network

c/o Alsace BioValley Parc d'Innovation
9 bd Gonthier d'andernach - 67400 Illkirch - FR

Website: www.biovalley.com
Phone: + 33 (0)3 90 40 30 00
Contact: BOYE Mona
Email: communication@alsace-biovalley.com

Overview: At the heart of Europe, bringing together three regions from France, Germany and Switzerland, BioValley is a Life Science network bringing together more than 600 companies, research institutes and renowned universities. The Franco-German-Swiss BioValley is a Life Science Network of six partners: BioPro (DE), BioValley Deutschland (DE), BioTechnologie Stiftung Freiburg (DE), i-net (CH), Biovalley Basel (CH) and Alsace BioValley (FR).

C9



Exhibitors

BLUMORPHO

17 rue de l'Amiral Hamelin - 75016 Paris - FR



Website: www.bmorpho.com
Phone: +33 (0) 6 75 80 08 29
Contact: ANDRIEUX GUSTIN Geraldine
Email: andrieux@bmorpho.com

Overview: BLUMORPHO is technology broker for innovation. We match technologies holders and innovation adopters in structuring the value chain from technology to market. Focused on value creation, we design an attractive ecosystem accelerating innovation adoption. We are working with technology holders, industrial businesses and investors. Based on our recognized expertise in smart systems, market trends and investment readiness, we generate business opportunities for our customers

Chelatec

1 rue Aronnax - 44821 Saint-Herblain - FR



Website: www.chelatec.com
Phone: +33 2 51 86 19 59
Contact: LE GAL Julien
Email: julien.legal@chelatec.fr

Overview: Chelatec provides customized services in the specific fields of radiolabeling and preclinical research. Our mission is to assist the pharmaceutical and biotechnology industry along the drug development process by using the radioactive tracer for Bioanalyses, Pharmacokinetics and ADME studies. The complementary services are proposed to address the need of in vivo data of drug candidates prior to the selection and drug development.

Catalent Pharma Solutions

14 Schoolhouse Road, Somerset - US



Website: www.catalent.com
Phone: +1 7326668072
Contact: GERRIZZO-MEGARR Lisa
Email: lisa.gerrizzo-megarr@catalent.com

Overview: Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer and animal health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent supplies over 70,000 billion doses of over 7,000 products to over 1,000 customers in over 80 countries.

CEA Tech

17 rue des martyrs - 38054 Grenoble Cedex 09 - FR



Website: www.cea-tech.fr
Phone: +33 (0)4 38 78 41 98
Contact: CUZIN Marc
Email: marc.cuzin@cea.fr

Overview: CEA Tech is the CEA's (the French Atomic Energy and Alternative Energy Commission) technology research unit. CEA Tech's three labs—Leti, Liten, and List—develop a broad portfolio of technologies for ICTs, energy, and healthcare. CEA Tech leverages a unique innovation-driven culture and unrivalled expertise to develop and disseminate new technologies for industry, effectively bridging the gap between the worlds of research and business.

Ceva Santé Animale

10, avenue de la Ballastière - 33500 Libourne - FR



Website: www.ceva.com
Phone: +33 (0)5 57 55 40 40
Contact: TESTET Valérie
Email: valerie.testet@ceva.com

Overview: Ceva is a global animal healthcare company, focused on the research, development, production and marketing of vaccines and pharmaceutical products for companion animals, livestock, swine and poultry. Driven to innovate, Ceva is one of the fastest growing top 10 animal healthcare companies. Our vision 'Together, beyond animal health' reaches far beyond animal health and welfare, and includes the fight against zoonoses and the development of human animal bonds.

CiToxLAB atlanbio

BP 563 - Evreux - FR



Website: www.citoxlab.com
Phone: +33 (0)2 32 29 26 26
Contact: FAURE Laurence
Email: laurence.faure@fr.citoxlab.com

Overview: CiToxLAB is a non-clinical CRO specialized in safety evaluation services that offers a comprehensive range of services for clients ranging from small biotech, chemical and agrochemical companies, to large global pharma companies worldwide. Atlanbio is a human sized CRO offering bioanalysis services (Chromatography and Immunochemistry), and Toxicokinetic / Pharmacokinetic evaluation. Atlanbio supports human and veterinary drug development programs for Pharmaceutical and Biotechnology companies.

Clever Life Science

Rue d'Alsace - BP 20 - 68250 Rouffach - FR



Website: www.cleverlifesci.com
Phone: +33 (0)3 89 49 56 60
Contact: EXEL David
Email: d.exel@cleverlifesci.com

Overview: Clever Life Sciences is a Data Analytics CRO and Web based clinical solutions provider for the BioPharma industry founded in 1998. CLS provide Accurate, Comprehensive and Cost effective Data Analytics Services (Data Management, Biostatistics, Medical Coding, Functional Service Provider). Our in-house Genius Web-based Solutions line features eCRF, ePRO and ePayment, our paperless sites contracts, invoices and payments solution management. CLS Expertise covers Clinical Development, Post-Marketing, Rescue, Safety and Epidemiologic studies across all major therapeutic areas.

Drugabilis

5 rue Jean-Baptiste Clément
92290 Chatenay-Malabry - FR



Website: www.drugabilis.com
Phone: +33 (0)1 46 61 28 50
Contact: VACUS Joël
Email: joel.vacus@drugabilis.com

Overview: Drugabilis is an established company with an expertise in Solid Form Characterization & Early Formulation. Our unique proprietary platforms include:

- Compound Drugability assessment
- Solid Form Optimization
- Oral Low Solubility Delivery Feasibility
- Injectable Delivery Feasibility
- Ocular Delivery Feasibility
- Other drug delivery technologies (dermal, vaginal...)

Over 11+ years, Drugabilis has worked for 130+ clients, from idea to the clinic, to resolve their varied issues.

Enterprise Lithuania

Gostauto str. 40A - LT-03163 - LT



Website: www.enterpriselithuania.com/en
Phone: +37 062 625 278
Contact: DUMBROVAS Karolis
Email: k.dumbrovas@enterpriselithuania.com

Overview: Enterprise Lithuania is the main organizer of Life Sciences Baltics 2016 - the only international forum in the Baltic region for world-class biotechnology, pharmaceutical and medical devices experts from all around the world. It provides a unique opportunity to explore the new horizons of partnerships, exchange ideas and seek progress through networking. Discover enormous potential and passion in the field of life sciences in Lithuania and the Baltic region - the gateway to emerging markets.

Erdyn

23 rue Vergniaud - 75013 Paris - FR



Website: www.erdyn.com
Phone: +33 (0)1 77 75 79 81
Contact: SEJOURNE Kathye
Email: kathye.sejourne@erdyn.fr

Overview: Erdyn is a leader consulting company specialized in innovation which aims to sustain growth and competitiveness through innovation. We help our customers in the health and biotech domain to take the right decisions in their innovation projects and in their business development. We offer: - technological and scientific expertise for technology scouting - innovation marketing and business development consulting for start ups and SMEs - collaborative projects set up and management

ETAP-Lab

13 rue du Bois de la Champelle
54500 Vandœuvre-lès-Nancy - FR



Website: www.etap-lab.com
Phone: +33 (0)3 83 44 46 35
Contact: VIOLE Nicolas
Email: nviolle@etap-lab.com

Overview: For 25 years, ETAP-Lab has been offering preclinical services in the fields of Neurology and Dermatology. Original rodent models developed on specific request of its customers are available. Predictive data are generated by associating translational biomarkers (bioassays, immunohistochemistry, in vivo imaging) with behavioral outcomes. ETAP-Lab is also committed to the validation of new translational models of neurodegenerative diseases and is looking for partnerships to support its research.

EU-JAPAN CENTRE for Industrial Cooperation

52 Rue Marie de Bourgogne - 1000 Bruxelles - BE



Website: www.eu-japan.eu
Phone: +32 (0)2 28 200 40
Contact: MICHELSON Jessica
Email: j.michelson@eu-japan.eu

Overview: The EU-Japan Centre for Industrial Cooperation is seeking to identify EU clusters and SMEs interested in starting and/or expanding their activities with/in Japan in order to present to them European Commission-funded support services. - Cluster/ SME missions to Japan (ICT, Bio, Nanotech) ; - Partnering support to identify potential in Japan (www.een-japan.eu) ; - Help/ Information desk (www.eubusinessinJapan.eu) ; Logistical support in Tokyo

Eurasanté

Parc Eurasanté - 310 Avenue Eugène Avinée
59120 Loos - FR



Website: www.eurasante.com
Phone: +33 (0)3 28 55 90 60
Contact: EVRARD Mathieu
Email: mevrard@eurasante.com

Overview: Eurasanté is the economic development agency focusing on biotech, medtech and healthcare activities in Northern France. Eurasanté assists French and foreign companies interested in developing their activities or setting-up a business in Northern France. We provide many services (market studies, administrative formalities...). Eurasanté also promotes the Eurasanté bio-business park, which already hosts 7 hospitals, 4 universities, 1 engineering and business school and more than 150 companies. It benefits from an exceptional location in the heart of Europe (near to Paris, London, Brussels...).

Eurofins Biopharma Product Testing



9 avenue de Laponie - 91978 Courtaboeuf Cedex - FR

Website: www.eurofins.com/pharma-services/biopharma-product-testing.aspx
Phone: +33 (0)7 87 96 64 54
Contact: CHAPUT Flavie
Email: flaviechaput@eurofins.com

Overview: Eurofins Product Testing Biopharma, under pharmaceutical Accreditation, offers analytical services in GMP environment : Development, validation or transfer of methods, Chemical and biochemical analyzes, Microbiology, Biosafety and biological activity testing, Preparation and storage of cell banks, Import and release of clinical batches, Storage of samples from -180 ° C to 70 ° C, with cyclic and photostability conditions, Tailor-made secondary packaging, labeling and randomization clinic.

GLOBAL CARE Initiative



Institut Pasteur - 28 rue du Docteur Roux - 75015 Paris - FR

Website: www.globalcare-initiative.com
Phone: +33 (0)1 45 68 88 61
Contact: COULOMB Bertrand
Email: bertrand.coulomb@globalcare-initiative.com

Overview: GLOBAL CARE Initiative is a non-profit consortium of 5 instituts Carnot dedicated to health: Curie Cancer (Cancer) , ICM (Brain & Spine Institute, CNS diseases), Voir & Entendre (Seeing and Hearing diseases), CALYM (Lymphoma) and Pasteur MI (Infectious diseases). These institutes have joined to combine their efforts in fostering their international research partnerships with the industry and other academic labs.

HNP Mikrosysteme

18 avenue de la Paix - 67000 Strasbourg - FR



Website: www.hnp-mikrosysteme.fr
Phone: +33 (0)3 88 64 27 24
Contact: PITROIS Myriam
Email: myriam.pitrois@hnp-mikrosysteme.fr

Overview: HNP Mikrosysteme is a German-based highly innovative company with over 78 employees. The company produces micro annular gear pumps which are ideally used where fast and highly precise dosage is required. These pumps are characterized by low pulse delivery, minimal dead volume, long service life, small dimensions, powerful materials and ease of maintenance. Due to chemical resistant materials used for m3r®-pumps, a chemical sterilization is possible.

HWI ANALYTIK GmbH

Rheinzaberner Str. 8 - 76761 Ruelzheim - DE



Website: www.hwi-pharma-solutions.com
Phone: +49 727 277 672 700
Contact: KERST Melanie
Email: sales@hwi-pharma-solutions.com

Overview: HWI pharma group provides a wide range of individual and specialised services in the pharmaceuticals field, in particular for drug substances, drug products and medical devices. Over the last 20 years, our company group has gained a wealth of regulatory and scientific knowledge and experience to support our clients. This is located in our 5 business areas - laboratory services, reference standard services, vigilance and quality services, API & drug development, and regulatory affairs services.

Exhibitors

ICSA Animal Health Carnot Institute

INRA Département Santé Animale
37380 Nouzilly - FR

Website: www.ic-sante-animale.com
Phone: + 33 (0)1 42 75 93 26
Contact: WACQUET Fanny
Email: fanny.wacquet@paris-inra.fr

Overview: ICSA is a research network which aims to support innovation, technology transfer and public-private partnership in the fields of infectious diseases, nutrition and genetics of livestock. ICSA offers businesses a range of integrated and multidisciplinary research skills to address the issues of animal health within the concept of «One Health».



Kaly-Cell

20A, rue du Général Leclerc - 67115 Plobsheim - FR

Website: www.kaly-cell.com
Phone: +33 (0)3 88 10 88 30
Contact: RICHERT Lysiane
Email: l.richert@kaly-cell.com



Overview: Kaly-Cell is a true partner in the field of hepatocytes for both drug development and cell therapy: Kaly-Cell offers a variety of in vitro and ex vivo contract services for drug candidate metabolism and safety evaluation. Kaly-Cell provides an extensive selection of high-quality liver products (including a biobank of tissue, subcellular fractions and hepatocytes from more than 500 donors) for drug metabolism and safety assessment.

ID2Santé

2 avenue Professeur Léon Bernard
CS 34317 - 35043 Rennes - FR

Website: www.id2sante.fr
Phone: + 33 (0)2 23 23 45 81
Contact: LE POCHER Hélène
Email: contact@id2sante.fr

Overview: ID2Santé supports innovation in the health sector in Bretagne (French region). We link up key players in research, healthcare and business to develop innovative projects. We provide support from the concept through to the end product approved for health market. We promote the health sector's expertise. ID2Santé is also the representative Atlanpole Biotherapies cluster in Bretagne. Expertises: medical technologies, e-health, biotechnologies pharma, nutrition, environment & health.



Knowmade

2405 route des Dolines
06902 Sophia Antipolis - FR

Website: www.knowmade.com
Phone: +33 (0)6 20 04 58 73
Contact: BARON Nicolas
Email: nicolas.baron@knowmade.fr

Overview: Knowmade is a Technology Intelligence and IP Strategy consulting company. We provide Patent Search, Patent Analysis, IP Landscape, Technology Scouting and Technology Transfer. We combine information search services, scientific expertise, powerful analytics and proprietary methodologies for analyzing patents and scientific information. With a solid focus on Biotech, Pharma and MedTech, Knowmade supports research laboratories, industrial companies and investors in their business development.



Infors AG

Rittergasse 27 - 4103 Bottmingen - CH

Website: www.infors-ht.com
Phone: +41 614 257 713
Contact: LEPRINCE Audrey
Email: a.leprince@infors-ht.com

Overview: INFORS HT is your specialist for bioreactors, incubation shakers and bioprocess control software. For your applications, we offer the right solutions: - Fermentation of microorganisms- Cell culture (mammalian/insect/plant/algae) - Biofuel- Parallel bioprocesses- Customized bioreactors and incubation shakers- Bioprocess control software- Qualification of bioreactors and incubation shakers Closeness to the customer, high quality, innovation and flexibility are our greatest strengths.



Lebas Industries

1 bis Rue Pierre et Marie Curie - Synergie Park
59260 Lezennes - FR

Website: www.lebas-industries.com
Phone: +33 (0)3 20 30 24 02
Contact: GAGNAIRE Jérémy
Email: dcm@lebas-industries.com

Overview: LEBAS INDUSTRIES is an engineering company which designs, builds and commissions labs, pilots or plants. Thanks to its skills in process, utilities, building, automation and supervision, electricity and instrumentation, LEBAS is an EPCC/EPCM contractor. Since 1977, LEBAS develops a process engineering and project management know-how applied to fermentation, separation, purification, concentration, drying... LEBAS INDUSTRIES offers a range of custom made bioreactors/fermenters from 5L to 300 m3.



INPI

15 rue des Minimes - CS 50001
92677 Courbovoie Cedex - FR

Website: www.inpi.fr
Phone: +33 (0)1 71 08 71 63
Contact: BORNE Philippe
Email: contact@inpi.fr

Overview: Training and awareness-raising for economic stakeholders and businesses concerning Industrial Property (IP) issues / Grant of IP rights / Assistance to businesses on their innovation projects / Active contribution to the fight against counterfeiting / Involvement in the development of IP rights. The INPI has developed its range of INPI COACHING services to help businesses discover Industrial Property or extend their IP activities, enabling them to create value from their innovation potential.



Libragen

Canal Biotech I - 3 rue des satellites
31400 Toulouse - FR

Website: www.libragen.com
Phone: + 33 (0)5 62 19 31 94
Contact: WAHLER Denis
Email: dwahl@libragen.com

Overview: With over 15 years expertise in meta DNA/RNA extraction and handling, bioinformatics analysis and data mining, Libragen offers services in metagenomics/ transcriptomics/ bioinformatics/ data mining / NGS Sequencing: 16s and Whole Genome Sequencing (WGS). Deep expertise in: - Skinmicrobiota; - Gut microbiota; - Mucosal epitheliums microbiota; - Biomarkers; - Production of metagenomic libraries; Sequencers: Illumina and Pacbio; - Bioinformatics and bioanalysis



Linksium

31 rue Gustave Eiffel - 38000 Grenoble - FR

Website: www.linksium.fr
Phone: +33 (0)4 57 13 81 50
Contact: SOUVERAIN Véronique
Email: veronique.souverain@linksium.fr



Overview: Linksium, is a major player in business development linked to technological innovation. Business players have a new access to public research results, OUR SINGULARITY: TECHNOLOGY TRANSFER & STARTUPS BUILDING This unique combination stimulates success of projects. We carefully select projects with valuable intellectual property inside. We promote projects with an unique 6 dimensions methodology.

Materials Institute Carnot Alsace

15 rue Jean Starcky - BP 2488
68057 Mulhouse - FR

Website: www.carnot-mica.fr
Phone: + 33(0)3 89 60 86 60
Contact: HEINRICH Marc
Email: marc.heinrich@uha.fr

Overview: Specialising in functional materials, surfaces and interfaces for Healthcare, the Carnot MICA Institute can support you when designing your products and can ensure every steps of the process, from material design to clinical trials. MICA's solutions are ideal for medical devices, pharmaceutical and diagnostics sectors, in the form of R&D programmes, services, consulting and technology transfers.



Medicen Paris Region

3/5 impasse Reille - Paris - FR

Website: www.medicen.org
Phone: + 33 (0)1 79 68 10 89
Contact: DECARME Alexia
Email: adecarme@medicen.org

Overview: With over 200 members, our goal is to increase the attractiveness of the Paris region, to strengthen the international competitiveness of the health sector and to develop the economic growth of our members in strategic markets through collaborative innovation. Since the cluster was created in 2005, 257 R&D projects have been accredited and funded by the French State and local authorities, for a total project budget of €1,4 billion and €468 million of public subsidies.



Merck

39 route industrielle de la Hardt -
67120 Molsheim - FR

Website: www.merckmillipore.com/GB/en
Phone: +33 (0)3 90 46 93 00
Contact: SAINT-ANDRIEU Julien
Email: julien.saint-andrieux@merckgroup.com

Overview :Merck is a leading science and technology company in healthcare, life science and performance materials. Around 40,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2014, Merck generated sales of €11.3 billion in 66 countries.



Merial

254 rue Marcel Merieux - 69007 Lyon - FR

Website: www.merial.com
Phone: +33 (0)4 7272 3000
Contact: AUDONNET Jean-Christophe
Email: jean-christophe.audonnet@merial.com

Overview: Merial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health and well-being of a wide range of animals. Merial is advancing progress and innovation in the animal health industry, providing products for both companion and production animals and responding to the unmet needs of newly emerging diseases. Merial employs 6,500 people and operates in more than 150 countries worldwide with over €2 billion of sales in 2014.



Nord FR Innovation Développement - NFID

323, boulevard du Président Hoover
59000 LILLE - FR

Website: www.jinnove.com
Phone : +33 (0)6 42 95 96 57
Contact: ASSEMAT Emeline
Email: eamasemat@nfid.fr

Overview: NFID is a resource and support center aimed at developing innovation and research development, entrepreneurship, creation and development of economic activities in Nord-Pas de Calais region. NFID runs "J'innove en Nord-Pas de Calais", the regional network which federates across the territory: poles of competitiveness and excellence, universities & colleges, research organizations, consular organizations, funding bodies and the protection of innovation, incubators, technology resource centers...



Nutrition Health Longevity Cluster

310 avenue Eugène Avinée - 59120 Loos - FR

Website: www.nhl-cluster.com
Phone: +33 (0)3 28 55 50 14
Contact: LABE Alexandre
Email: alabe@pole-nsi.org

Overview: Nutrition health Longevity (NHL) Cluster aims at federating public and private partners around R&D projects leading to innovative products at the crossroads of the food and biotechnology sectors. Key player interfacing nutrition and health, NHL provides support to its members in designing, developing and financing the products and processes of the future. NHL gathers a dynamic network focusing on today's main health issues. NHL Cluster, your innovation partner



OCR

80 rue du Docteur Yersin - Parc Eurasanté
59120 Loos - FR

Website: www.oncovet-clinical-research.com
Phone: +33 (0)6 63 51 39 71
Contact: DUBRUQUE Matthieu
Email: mdubruque@oncovet-clinical-research.com

Overview: OCR is specialized in the design and monitoring of clinical trials of owned-Dogs & Cats with naturally occurring diseases for assessment of drug candidates for Human Health (Comparative Medicine Studies) & Animal Health (Pilot & Pivotal Clinical Trials) OCR provides to Pharma Players highly predictive animal models (owned-Dogs & Cats) of Human diseases (Cancer, Inflamm., Dermato., Cardio., Neuro., ...) OCR acts as a full Vet-CRO for Vet Players for the clinical development of new drugs for Pets.



Exhibitors

ONCOLille

Maison Régionale de la Recherche Clinique
Rue du Pr. Laguesse, 59037 Lille Cedex - FR

Website: www.oncolille.fr
Phone: +33 (0)3 20 44 63 46
Contact: VANLEENE Maximilien
Email: maximilien.vanleene@chru-lille.fr

Overview: ONCOLille is an Integrated Research consortium. In Oncology (SIRIC) federating fundamental, translational and clinical researchers in the fields of biology, imaging, animal models, Methodology and human sciences. It involves around 20 academic and clinical laboratories in the Lille area and 300 scientists and clinicians. They all collaborate to improve our understanding in modern oncology through 3 research programs: «tumor resistance», «tumor dormancy» and a program in «Social Sciences and Humanities».

PRECIGENICS

EGID Université Lille2
1, Place de Verdun - 59045 Lille - FR

Phone: +33 (0)3 20 97 42 62
Contact: MEZDOUR Hafid
Email: hafid.mezdour@univ-lille2.fr

Overview: Precigenics is a genomic spin-off of UMR8199/Ligan-Personalized Medicine platform (CNRS). Led by Philippe Froguel, a leading academic expert in human genetics, Ligan-PM provides researchers cost-effective genome sequencing and data analysis. Precigenics is targeting the medical community by providing state of the art integrated genomic services based on NGS and metabolomics that will make a significant difference in disease prediction, prevention and therapeutics towards personalized medicine.

PRECIGENICS

Original Process

21 rue Saint André - 59000 Lille - FR

Website: www.original-process.com
Phone: +33 (0)3 20 21 88 90
Contact: DELPORTE Isabelle
Email: isabelle.delporte@original-process.com

Overview: Original Process, specialist of the animal digestive microbiota since 40 years. From its exclusive technology FAP® (Factor Assimilation Process), Original Process develops exclusive Processes to produce ProbioactiFAP® (raw materials and a range of complementary feeds). Naturally rich in prebiotic and postbiotic molecules, these products stimulate primarily some beneficial microorganisms of the digestive flora and their activities to the detriment of the pathogenic, throughout the digestive tract.

Prosthesis Valley

Pôle technologique Sud-Champagne Lavoisier
52800 Nogent - FR

Website: www.prosthesis-valley.org
Phone: +33 (0)3 25 31 52 52
Contact: JUPPIN Christophe; BIGUET David
Email: c.juppin@haute-marne.cci.fr; contact@cluster-nogentech.com

Overview: With more of 35% of world production of orthopedic implants and instrumentations, Southern Champagne area and Prosthesis Valley, its European cluster, are a key player in the medical devices market. Prosthesis Valley includes companies specialized in medical devices (prosthesis, ancillary, instruments of surgery and related trades). Major MDD OEM and companies specialized in MD manufacturing and/or subcontracting are established in Champagne Region.

Prosthesis Valley

Oroxcell SAS

102, avenue Gaston Roussel
93230 Romainville - FR

Website: www.oroxcell.com
Phone: +33 (0)1 41 83 72 22
Contact: DINI Christophe
Email: christophe.dini@oroxcell.com

Overview: For more than a decade Oroxcell has strived to offer industry-leading ADME/Tox services that provide physiologically relevant results, from screening to GLP compliant studies. Our clients and partners include Pharma, Dermo-Cosmetic, Home & Care products, Medical Device, and Chemical Industries.

ProteoGenix

15 rue de La Haye - 67300 Schiltigheim - FR

Website: www.proteogenix.science
Phone: +33 (0)3 90 20 54 70
Contact: GODEL Thomas
Email: tgodel@proteogenix.fr

Overview: With more than 12 years' experience, ProteoGenix accounts for a unique and customized access to 5 service types structured around: - Recombinant protein purification (5 systems) - Recombinant Antibody engineering - Peptide synthesis - Monoclonal and Polyclonal antibody development - Gene synthesis Our interdisciplinary experience around four pillars "Antibody, Protein, Gene and Peptide" and our optimal size structure allow us to deliver perfectly validated and characterized reagents.

ProteoGenix

Polepharma

11 rue du Cardinal Pie - 28000 Chartres - FR

Website: www.polepharma.com
Phone: +33 (0)2 47 36 63 41
Contact: EHRHARDT Sophie
Email: sophie.ehrhardt@polepharma.com

Overview: The role of Polepharma is to stimulate the industrial and economic development of the companies involved in the first pharmaceutical industrial cluster in France, through actions promoting Competitiveness, Innovation and the vitality of our Network. Missions: Favoring a joint industrial culture, gathering together academic research and industry to create social-economic value on the territory of Polepharma; - Accelerating the collaborations between academic research and industry

POLEPHARMA

Pulsalys - SATT Lyon St Etienne

47 boulevard du 11 novembre 1918 - 69625 Villeurbanne Cedex - FR

Website: www.pulsalys.fr
Phone: + 33 (0)4 26 23 56 60
Contact: BONNAZ Aurélie
Email: aurelie.bonnaaz@pulsalys.fr

Overview: PULSALYS's main activity consists in selecting, investing and transferring the results from research (Laboratories of Lyon University) to industrials or start-up. PULSALYS is supporting the project during all the development phases: invention, protection (patent) and we gives you all the resources and competences to validate the opportunity, set a prototype and the concept proof (up to 250k€ per project) to transfer the project to an existing company or a start-up.

PULSALYS

R&D dating for Animal Health and Innovation - SIMV

50 rue de PARADIS - 75010 Paris - FR

Website: www.simv.org
Phone: +33 (0)1 53 34 43 43
Contact: STEFFEN Laetitia
Email: l.steffen@simv.org

Overview: The French association for animal health industry (SIMV) represents companies (on the French market) of medicines and diagnostics for pets and for farm animals. France is the European leader in research and manufacture of veterinary medicines and diagnostics (with sales of 867 million euros in 2014). The SIMV created in 2014 the first European business convention dedicated to animal health, the «R&D» dating for animal health and innovation.



RONDOL

8 place de l'hôpital - 67000 Strasbourg - FR

Website: www.rondol.com
Phone: +33 (0)6 37 81 61 85
Contact: BRUGGEMAN Donatien
Email: donatien@rondol.com

Overview: Rondol develops at the micro scale a full range of Hot Melt Extrusion (HME) machines together with all necessary upstream and downstream equipment. Our program contains a vast range of single and twin screw extruders and related up- and downstream equipment, injection molding machines and presses. We have yet become a trustful partner for Pharma and Medtech companies for developing machines for a range of pharmaceutical dosage forms applications (tablets, capsules, films, and implants ...)



RD-BIOTECH, Your R&D partner in biotechnology

3 rue Henri Baigue - 25000 Besancon - FR

Website: www.rd-biotech.com
Phone: +33 (0)1 81 53 88 37
Contact: MERCIER Sylvie
Email: sylvie.mercier@rd-biotech.com

Overview: RD-Biotech is a French CRO that proposed services in biotechnology: Bioproduction: mAb, recombinant proteins, plasmids Research contracts: cell line, hybridoma development, cloning humanization, ELISA Biotech Investissement, majority shareholder of RD-BIOTECH, acquired Diaclone SAS on 2012: a wide range of mAbs & Immunoassays SynAbs, a Belgium company. Joined the Group last month. Its expertise in rat mAb greatly complement the expertise of the sister companies in the field of monoclonal antibodies.



Recipharm

Lagervägen 7 - 136 50 Jordbro - FR

Website: www.recipharm.com
Phone: +33 (0)6 30 88 69 92
Contact: TAHIRI Amine
Email: amine.tahiri@recipharm.com

Overview: Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 2,200 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures more than 400 different products to customers ranging from Big Pharma to smaller research- and development companies.



RWS Translations

Europa House, Chiltern Park, Chiltern Hill - SL9 9DB - Chalfont St. Peter - UK

Website: www.rws.com
Phone: +44 (0)1 753 480 200
Contact: BROMHEAD Julia
Email: julia.bromhead@rws.com

Overview: RWS is the world's leading provider of translations and offers a unique combination of IP and language support services. Its Medical Translation Division is the one-stop solution for all your language needs, providing a unique combination of translation and interpreting services for life science companies and CROs worldwide. Specialist teams include medically qualified translators, interpreters and in-house proofreaders. We can handle 200 language combinations.



SATT Aquitaine Science Transfert

162 avenue Albert Schweitzer - 33600 Pessac - FR

Website: www.ast-innovations.com
Phone: +33 (0)5 56 42 94 85
Contact: CHUSSEAU Maylis
Email: contact@ast-innovations.com

Overview: Aquitaine Science Transfer is the SATT Aquitaine (Company for Technology Transfer Acceleration), founded at the initiative of french government with the objective to develop public research valorisation and improve the technology transfer process. Aquitaine Science Transfert skills cover all stages of technology transfert: investment in the proof of concept, management and transfer of intellectual property, negotiation of partnership research contracts and support to the creation of companies.



Réseau SATT

C/O IDF INNOV - 37 rue de Lyon - 75012 Paris - FR

Website: www.satt.fr
Phone: + 33 (0)3 28 36 89 66
Contact: BRILLANT Caroline
Email: caroline.brillant@sattnord.fr

Overview: The Accelerator of Technology Transfer Companies (Les Sociétés d'Accélération de Transfert de Technologie or SATT) are French private TTOs, SATTs have a challenging mission to accelerate the translation of research into innovations. SATTs are the privileged conduit to license emerging technologies from universities and public research centers. Their aim is to enhance the value and to accelerate the process of technology transfer from publically funded research towards industry.



SATT AxLR

1000 avenue Agropolis
34394 Montpellier cedex 5 - FR

Website: www.axlr.com
Phone: + 33 (0)4 67 04 37 46
Contact: CRITON Marc
Email: Marc.Criton@axlr.com

Overview: AxLR is a technology transfer acceleration company. Our specialty is helping innovative projects derived from academic research reach maturity and commercialization. We work with the main public-sector research laboratories in France's Languedoc-Roussillon area, one of the most dynamic locations in Europe, with over 200 laboratories and some 12,000 researchers. AxLR reduces R&D risks for companies.



SATT Conectus Alsace

650 Bd Gonthier d'Andernach - 67400 Illkirch - FR



Website: www.conectus.fr
Phone: +33 (0)3 68 41 12 79
Contact: DENAT Emilie
Email: emilie.denat@satt.conectus.fr

Overview : SATT Conectus Alsace is the single entry point for companies and exclusive business partner to access to all the innovations originating from public research institutions in Alsace, one of the top ranked regions in France for the excellence of research. It is also the partner of choice to access a unique and broad range of highly advanced knowhows, skills and facilities, within a favourable geographic position in the heart of Europe (Alsace borders Germany and Switzerland).

F8

SATT Grand Centre

8, rue Pablo Picasso
63000 Clermont-Ferrand - FR



Website: www.sattgc.com
Phone: +33 (0)4 73 60 18 30
Contact: BOULARAND Marjorie
Email: contact@sattgc.com

Overview: SATT Technology Transfer Organisation (Center of France) organises early detection of inventions and guarantees its exclusivity. SATT Center of France reveals the potential of future innovations for a successful transfer to business in providing financial and technical supports. Located in Clermont-Ferrand, SATT Center of France works with 7 Universities, 4 Régions, 7 Institutes of Technology and 8500 Researchers and Professors.

F8

SATT IDF Innov

37 rue de Lyon - 75012 Paris - FR



Website: www.idfinnov.com
Phone: + 33 (0)1 44 23 21 50
Contact: SERVANT Marie-Christine
Email: mcs@idfinnov.com

Overview: IDF Innov is a private TTO with exclusive rights on technology detection, seeding and commercialization over a vast academic territory in the Paris Metropolitan Area. This territory is strong of more than 17000 researchers, clinicians and PhDs, and hosts the strongest cluster for clinical expertise in France. IDF Innov operates as a seeding funds and is committed to facilitate the due diligences for IP related private-public partnering and start-up creation.

F8

SATT Lutech

24 boulevard de l'hôpital - 75005 Paris - FR



Website: www.sattlutech.com
Phone: +33 (0)1 78 94 68 51
Contact: GUILLAUME Jérémy
Email: jeremy.guillaume@sattlutech.com

Overview: Created as a part of the «Investissement d'Avenir» program, SATT Lutech is a private company specialized in technology transfers : this company detects, protects, develops and commercializes the skills and research results coming from its partner institutions. Its mission is to facilitate the emergence of innovations with a real economic and/or social potential. Lutech invests in the development of proof of concept and/or prototype to support innovative projects, from laboratory to market.

F8

SATT Nord

2 Rue du Priez - 59000 Lille - FR



Website: www.sattnord.fr
Phone: +33 (0)3 28 36 04 68
Contact: BRILLANT Caroline
Email: caroline.brillant@sattnord.fr

Overview: Satt Nord (Technology Transfer Office) covers the whole value chain of technology transfer: increasing the awareness of researchers to innovation, sourcing high potential inventions in academic research labs, cofunding private-public collaborations, financing proof of concept and prototyping projects, as well as marketing "ready to industrialize" technologies through licensing out agreement, or creating start-up businesses. It is a tool for economic development through innovation.

F8

SATT Ouest Valorisation

14C rue du Patis Tatelin - 35000 Rennes - FR



Website: www.ouest-valorisation.fr
Phone: +33 (0)2 99 87 56 18
Contact: PERIER Charlotte
Email: communication@ouest-valorisation.fr

Overview: Ouest Valorisation – Office of Technology Transfer (OTT) was created in the "Future Investments" project call managed by Ministry of Higher Education and Research. Its aim is to propose to companies attractive innovation means from the public research. Ouest Valorisation's team simplifies the access of the companies to research laboratories in order to develop good collaborative projects or to get access to high professional skills and high level scientific equipment.

F8

SATT Paris-Saclay

86, rue de Paris - 91400 Orsay - FR



Website: www.satt-paris-saclay.fr
Phone: +33 (0)1 84 00 00 25
Contact: FRETIGNY Carole
Email: communication@satt-paris-saclay.fr

Overview: SATT PARIS-SACLAY : a bridge between research and business. SATT Paris-Saclay was established in 2014 in Orsay, France, to help create value from research at Paris-Saclay University and support the transfer of new technologies and know-how to industry. With funding provided through the French government's economic stimulus package (Investissements d'avenir), SATT Paris-Saclay is also tasked with leveraging innovation to spur local economic growth and job creation.

F8

SATT Sud Est

8 rue Sainte Barbe CS 10422
3205 Marseille Cedex 01 - FR



Website: www.sattse-technologies.com
Phone: +33 (0)4 13 24 66 10
Contact: PICARD Rémi
Email: remi.picard@sattse.com

Overview: SATT Sud Est helps companies to boost their competitiveness through innovation stemming from public research of South Eastern France. Its core business involves bringing inventions developed by its shareholder research bodies to readiness on intellectual property, market and proof of concept levels. SATT is focused on bridging the technology gap between these innovative technologies and their industrial-scale production and transferring them through granting operating licenses to companies.

F8

Soladis Clinical Studies

Soladis Paris Agency - 94 rue Saint Lazare
75009 Paris - FR



Website: www.soladis.fr
Phone: +33 (0)1 86 21 67 17
Contact: PERRUSSEL Anthony
Email: aperrussel@soladis.fr

Overview: Soladis and its BU dedicated to clinical studies management Soladis Clinical Studies provide statistical and clinical services to Life Sciences actors (Pharma, MedDev, Biotech, Agro, Cosmetic) at any stage of the product life cycle: R&D, Preclinical & Clinical development, Production, and Marketing/PMS. Combining both Medical and Statistical expertise working in an efficient synergy, Soladis CS, highly experienced full-service CRO, carries out your studies from protocol to report or publication.

A5

SomaLogic, Inc.

2945 Wildemess Pl
80301 Boulder Colorado 80301 - US



Website: www.somallogic.com
Phone: +1 8 77 99 02 626
Contact: MIURA Yumi
Email: ymiura@somallogic.com

Overview: SomaLogic's SOMAmer® protein-binding reagents combine the specificity and affinity of antibodies with the manufacturing consistency of DNA, resulting in a superior protein binding reagent. Our SOMAscan™ assay, based on SOMAmers, can monitor over 1,310 proteins in a small sample. SOMAscan's breadth and depth of coverage offers unprecedented biomarker discovery capabilities.

E8

Teclis

46bis chemin du Vieux Moulin
69160 Tassin La demi-Lune - FR



Website: www.teclis-instruments.com
Phone: +33 (0)4 74 70 18 51
Contact: BESSON-THURA Séverine
Email: contact@teclis-instruments.com

Overview: Teclis is a science-based company with a 25-year international expertise in physical measurements of molecular interactions. Teclis offers solutions to life sciences industries at different stages of their value chain, from drug discovery to detailed molecule assessment, to screening of compounds for the choice of a successful galenic formulation process. Teclis also supports its customers to find their best molecular combination to optimize their drug targeting and delivery construct.

B4

Theradis Pharma

41 Chemin des Presses - ZA des Presses - 06800 Cagnes sur Mer - FR



Website: www.theradispharma.com
Phone: +33 (0)4 97 02 09 39
Contact: RAFFY Chantal
Email: chantal.raffy@theradispharma.com

Overview: Theradis Pharma is a Pharmaceutical Company offering management of clinical supplies, centralisation of analysis and all logistic support services for Clinical Trials. With over 20 years' experience in Clinical trials, the International Theradis Pharma team manages and coordinates all the actors of the supply chain, in compliance with the International and local regulatory requirements and according to the budget allocated to the project.

F9

TKM

4 Rue Leon Beridot - 38500 - Voiron - FR



Website: www.izi'nov.com
Phone : +33 (0)4 76 06 57 00
Contact: FRANKE Cindy
Email: cf@tkm.fr

Overview: Since 2004, TKM addresses innovation and intelligence. Our turnkey products, IZI'NOV, make the innovation process more available and prove by example that companies need to make systematic use of available objective information to succeed better. Customised advice and service : we address the most complex issues at all stages of innovation. Analysis Software , IP Metrix: for decision makers, we provide a high-performance search, visualisation, analysis and data share with Big Data capacities.

E13

Toulouse Tech Transfer

MRV - 118 route de Narbonne
31432 Toulouse - FR



Website: www.toulouse-tech-transfer.com
Phone: +33 (0)5 62 25 50 60
Contact: METAIS Claire
Email: metais@toulouse-tech-transfer.com

Overview: Following a French National initiative, 14 technology transfer companies called SATTs have been created to boost the technology transfer. Toulouse Tech Transfer was created in January 2012 as one of the first five SATTs. TTT's core business is to invest in technology maturing programs (proofs of concept) based on academic research results of the Midi-Pyrénées region. The objective of these investments is to license the matured technologies and products to businesses.

F8

VIRBAC

13ème Rue - L.I.D - 06517 Carros - FR



Website: www.virbac.com
Phone: +33 (0)4 92 08 71 00
Contact: PAPIEROK Gérard Marie
Email: gerard-marie.papierok@virbac.com

Overview: Founded in 1968 by a French Veterinarian, Virbac is an independent pharmaceutical laboratory dedicated to animal health. Ranked 7th worldwide, the company is present in more than 100 countries, offering a comprehensive and practical range of products and services covering the majority of species and pathologies. Virbac innovation based on both technological advances and listening to customers, relies on reactive production facilities which meet the highest international quality standards.

C10

ZOETIS

23,25 rue du docteur Lannelongue
75014 Paris - FR



Website: www.zoetis.com
Phone: +33 (0)1 70 80 80 40
Contact: QUENTRIC Anne-France
Email: anne-france.quentric@zoetis.com

Overview: Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2014, the company generated annual revenue of \$4.8 billion.

C10

Zymo Research Europe GmbH

Mülhauser Str. 9
79110 Freiburg im Breisgau - DE



Website: www.zymoresearch.de
Phone: + 49 (0) 761 6006871 0
Contact: HOFES Nadja
Email: nhoefs@zymoresearch.de

Overview: Zymo Research Europe - Germany was established in 2009. Originally intended as a distribution support hub for Europe and the Middle East, it promoted Zymo's vision of "The Beauty of Science is to Make Things Simple." Whether Epigenetics, DNA, RNA, E. coli, or Yeast based research, the philosophy remains the same: Provide the highest quality products in the industry while ensuring they are both simple to use and reliable in their performance.

E2

They support us

Media




Supporters



Find your way through BioFIT

Ground Floor



First Floor



5th
edition



Biofit

FOSTERING
INNOVATION
& TRANSFER

LILLE **2016** - FRANCE

A 360° approach to build Life Sciences partnerships

Save the Date

**November 30th &
December 1st, 2016**



**Back in
Lille
France**

Organized by



Marion SIGIER
Event Manager
biofit@eurasante.com
+33 (0)3 28 55 90 60

www.biofit-event.com